ASCO Releases Opinion on Hormonal Therapy for Castrate-resistant Prostate Cancer

Share this content:
ASCO published a provisional clinical opinion regarding second-line hormonal therapy for men with non-metastatic or minimally symptomatic metastatic CRPC.
ASCO published a provisional clinical opinion regarding second-line hormonal therapy for men with non-metastatic or minimally symptomatic metastatic CRPC.

The American Society of Clinical Oncology (ASCO) offered a provisional clinical opinion (PCO) regarding second-line hormonal therapy for men with non-metastatic or minimally symptomatic metastatic castration-resistant prostate cancer (CRPC). The PRO was published in the Journal of Clinical Oncology.1

ASCO recommends that men with CRPC maintain castrate-levels of testosterone. There are, however, no data to support the use of second-line hormonal therapy among men with non-metastatic CRPC, though agents such as anti-androgens and CYP17 inhibitors can be considered for patients at a high risk of metastasis.

Abiraterone or enzalutamide are recommended as second-line hormonal therapies for men with CRPC with radiographic evidence of metastases.

The PCO does not provide guidance on the preference or sequencing of these agents due to a paucity of data. ASCO suggests sipuleucel-T, docetaxel plus prednisone, or radium-223 as alternative options.

The PCO recommends that clinicians assess PSA levels every 3 months for men with a rapid PSA doubling time, velocity, or with documented metastases. Recommended imaging modalities include a bone scan with CT or MRI of the abdomen and pelvis.

ASCO recommends against routine radiographic imaging unless the results would alter treatment decisions, or if prostate cancer-specific symptoms develop or worsen.

RELATED: PSA Density More Accurate Than PSA for Predicting Prostate Cancer

This PCO considers data from 6 phase 3 randomized controlled trials and expert consensus opinion. It will be updated as results from ongoing trials are published.

Reference

  1. Virgo KS, Basch E, Loblaw DA, et al. Second-line hormonal therapy for men with chemotherapy-naïve, castration-resistant prostate cancer: American Society of Clinical Oncology provisional clinical opinion. J Clin Oncol. 2017 Apr 25. doi: 10.1200/JCO.72.8030 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters